Standard Medical Management in Secondary Prevention of Ischemic Stroke in China

Conditions

Stroke

Keywords

Stroke, Prevention Therapy

Brief summary

The purposes of the study are to analyse the cross-section data of secondary stroke prevention in China and to carry out a standard medical management including medicine and interactive education program,and to evaluate the efficacy and safety of the standard medical management in secondary stroke prevention.

Yuze Cao, Mengyu Zhang, Lixin Zhou, Ming Yao, Bin Peng et al. (8 authors)

Frontiers in Neurology2019-04-096 citations

10.3389/fneur.2019.00336

Elevated Fasting Blood Glucose Is Predictive of Poor Outcome in Non-Diabetic Stroke Patients: A Sub-Group Analysis of SMART

Ming Yao, Jun Ni, Lixin Zhou, Bin Peng, Yi‐Cheng Zhu et al. (7 authors)

PLoS ONE2016-08-0563 citations

10.1371/journal.pone.0160674

Implementation of a Structured Guideline–Based Program for the Secondary Prevention of Ischemic Stroke in China

Bin Peng, Jun Ni, Craig S. Anderson, Yi-Cheng Zhu, Yongjun Wang et al. (15 authors)

Stroke2014-01-0361 citations

10.1161/strokeaha.113.001424

Standard medical management in secondary prevention of ischemic stroke in China (SMART).

Peng B, Zhu Y, Cui L, Ni J, Xu W, Zhou L, Yao M, Chen L, Wang J, Wang Y, Pu C, SMART Study Group.

2011-10-0112 citations

10.1111/j.1747-4949.2011.00648.x

Interventions

DRUGAspirin / Clopidogrel, Atorvastatin / Simvastatin

Standard Medical Management,including antiplatelet agents(Aspirin 75\ 150mg/day or Clopidogrel 75mg/day),statins(Atorvastatin 20mg/day or Simvastatin 20mg/day),risk factor lowering agents (antihypertension agents:Amlodipine 5mg/day or Benazepril 10mg/day or Valsartan 80mg/day or Nifedipine 30mg/day or Indapamide 2.5mg/day,antidiabetic agents: Metformin 0.5 tid or Glipizide 5mg tid or Acarbose 50mg tid )if necessary,interactive education program (Online medical education program, health behavior guide) .

DRUGAsprin / Clopidogrel, Atorvastatin / Simvastatin

Antiplatelet agents(Aspirin 75\ 150mg/day or Clopidogrel 75mg/day),statins(Atorvastatin 20mg/day or Simvastatin 20mg/day),risk factor lowering agents (antihypertension agents:Amlodipine 5mg/day or Benazepril 10mg/day or Valsartan 80mg/day or Nifedipine 30mg/day or Indapamide 2.5mg/day,antidiabetic agents: Metformin 0.5 tid or Glipizide 5mg tid or Acarbose 50mg tid )if necessary

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

PREVENTION

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

No

Inclusion criteria

1. Ischemic cerebral infarction or TIA within 30 days. 2. Aged above 18 years old. 3. Hospitalized. 4. Cranial CT or MRI scan exclude intracranial hemorrhagic diseases 5. Stable clinical and neurological conditions. 6. A Modified Rankin score less than 4 at enrollment 7. Informed consent is obtained.

Exclusion criteria

Patients will be excluded from entry if any of the criteria listed below are met 1. Documented stroke caused by conditions other than atherosclerosis, ie, surgical or vascular intervention procedure. 2. Severe co-morbid or unstable medical condition, ie, heart failure, respiratory failure and renal failure, severe liver dysfunction, malignancy with likelihood of death within the next 2 years 3. Significant memory or behavioural disorder, ie, Alzheimer disease, etc, daily care needed. 4. A Modified Rankin score is more than 4 5. Concurrent participation in another clinical trial 6. Pregnant 7. Unable to give informed consent.

Design outcomes

Primary

Measure	Time frame
Success Rate of standard medical management	1 year after enrolled

Secondary

Measure	Time frame
Ischemic stroke	1 year after enrolled
Non-fatal acute coronary syndrome	1 year after enrolled
Transient Ischemic Attack	1 year after enrolled
Hemorrhagic Stroke	1 year after enrolled
All-cause Death	1 year after enrolled

Countries

China

Outcome results

None listed